Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells

Xue-mei WU1,3, Xiang-qiang SHAO1,3, Xian-xin MENQ2, Xiao-na ZHANG2, Li ZHU1, Shi-xu LIU1,3, Jian LIN1,3, Hua-sheng XIAO1,2,*

1The Center of Functional Genomics, Key Laboratory of Systems Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China; 2National Engineering Center for Biochip at Shanghai, Shanghai 201203, China; 3Graduate University of Chinese Academy of Sciences, Shanghai 200031, China

Aim: To investigate the involvement of microRNAs (miRNAs) in intrinsic drug resistance to hydroxycamptothecin (HCPT) of six gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS).

Methods: A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs.

Results: The sensitivity to HCPT was significantly different among the six cell lines. In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7. Their target genes were related to cancer development, progression and chemosensitivity. Moreover, 307 genes were differentially expressed in HCPT-resistant cell lines, including apoptosis-related genes (BAX, TIAL1), cell division-related genes (MCM2), cell adhesion- or migration-related genes (TIMP2, VSNL1) and checkpoint genes (RAD1). The combined analysis revealed 78 relation pairs between the miRNAs and mRNAs.

Conclusion: Hierarchical clustering showed that the miRNA and mRNA signatures in our results were informative for discriminating cell lines with different sensitivities to HCPT. However, there was slightly lower correlation between the expression patterns of the miRNA and those of the predicted target transcripts.

Keywords: hydroxycamptothecin (HCPT); gastric cancer; microRNA; signature; drug resistance; gene expression regulation; cluster analysis; messenger RNA
been reported to be related to the resistance to CPTs.

MiRNAs are a class of non-coding RNAs that are 21 to 25 nucleotides in length and function as regulators of gene expression. Recently, miRNAs have been identified as oncogenes or tumor suppressors[10, 11], and they have been regarded as potential drug targets[12] due to many of them being located at the fragile sites of chromosomes or cancer-associated genomic regions[13]. Bertino et al first introduced the idea of “miRNA pharmacogenomics,” which is defined as the study of miRNAs and polymorphisms affecting miRNA function to predict drug response and improve drug efficiency[14]. MiRNA misexpressions or mutations result in a gain or loss of miRNA function and, therefore, a downregulation or upregulation of the target protein, which is involved in the drug response. In previous studies, miR-24, miR-21, let-7a, miR-214, miR-221, miR-222, miR-328, and miR-27a have been reported to be involved in the regulation of chemosensitivity[15]. However, there have been no reports regarding miRNAs and their involvement in the resistance to CPTs of gastric cancer.

To find the miRNAs that are involved in intrinsic resistance to 10-hydroxycamptothecin (HCPT), we conducted a miRNA pharmacogenomics study on HCPT by performing a genomewide expression profiling of the miRNAs and mRNAs in six different gastric cancer cell lines. Our study provides a resource for integrated chemo-genomic studies that aimed to elucidate the molecular markers for personalized therapy and to understand the mechanisms of HCPT resistance.

Materials and methods

Cell culture

Six human gastric adenocarcinoma cell lines, BGC-823 (low-differentiated human gastric adenocarcinoma cell line), SGC-7901 (moderate-differentiated human gastric adenocarcinoma cell line), MGC-803 (low-differentiated human mucinous gastric carcinoma), HGC-27 (undifferentiated human mucinous gastric carcinoma), NCI-N87 (well-differentiated human carcinoma cell line) and AGS (low-differentiated human gastric adenocarcinoma cell line), were obtained from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China. The six cell lines were all derived from patients who had received no prior therapy. The cells were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum (Gibco BRL, Grand Island, NY) at 37 °C in 5% CO₂.

SRB assay

Cells were seeded in 96-well plates with 100 µL (5 000 to 10 000 cells/well) for 24 h and then exposed to freshly prepared HCPT (HSFY Pharma, China) at a final concentration that was 0.01, 0.1, 1, 10, and 100 times the human peak plasma concentration for HCPT (1.0 µg/mL). Simultaneously, one plate of each cell line was fixed with TCA. The cells were then incubated for 48 h, and their viability was assessed using the Sulforhodamine B (SRB) assay (Sigma, St Louis, MO). The absorbance at 515 nm (OD₅₁₅) was read using the automated plate reader. Seven OD₅₁₅ were measured: at time zero (Tz), the growth of control cells (C), and the growth in the presence of the drug at the five concentration levels (Ti). The percentage growth inhibition was calculated as [(Ti–Tz)/(C–Tz)]×100, when Ti/≥Tz; [(Ti–Tz)/Tz]×100, when Ti<Tz. The concentration resulting in a 50% reduction in the net protein increase in control cells during the drug incubation (GI50) was calculated using the percentage growth inhibition curve. All of the experiments were individually performed in triplicate.

Total RNA extraction and quality assessment

The cells were cultured for 24 h and then collected for total RNA extraction. Total RNA was isolated using the mirVana™ miRNA Isolation Kit (Ambion, Austin, Texas) following the manufacturer’s instructions. Then the RNA quantity was determined using Nanodrop1000. The RNA quality was assessed using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, California). All of the samples were assayed and qualified in triplicate using the miRNA microarray and DNA oligonucleotide microarray.

MiRNA microarray profiling

The input for Agilent’s miRNA labeling system was 100 ng total RNA. After dephosphorylation and denaturation, the total RNA was labeled with cyanine 3-pCp and then hybridized to Agilent Human miRNA Microarray V2 using the miRNA Complete Labeling and Hyb Kit (Agilent, Santa Clara, California). After hybridization for 20 h, the slides were then washed using the Gene Expression Wash Buffer Kit (Agilent, Santa Clara, California) and scanned using an Agilent Scanner. The images were processed and analyzed with Agilent Feature Extraction Software.

The raw data were normalized using quantile normalization and then analyzed in GeneSpring GX (zcomSilicon Genetics, Redwood City, CA, USA). Statistical analysis using ANOVA was conducted to compare the differentially expressed miRNAs.

Whole genome gene expression microarray

Gene expression profiles were analyzed using the Affymetrix HG-U133+PM Array Plate (Affymetrix, Santa Clara, CA). Three biological replicates of each cell line were assayed. The probes were labeled, hybridized and scanned according to the manufacturer’s instructions. The data were extracted through Expression Console (Affymetrix, Santa Clara, California). Data normalization and analysis were performed in GeneSpring GX software as mentioned above.

Quantitative real-time PCR (qRT-PCR)

For the miRNA, the reverse transcription of RNA was conducted using the miScript Reverse Transcription Kit. The cDNA serves as the template for real-time PCR analysis using a miScript Primer Assay in combination with the miScript SYBR Green PCR Kit (Qiagen, Germany). For the mRNA, the total RNA was reversed transcribed using the OneStep RT-PCR Kit. Then the cDNA served as the template for the real-time PCR analysis using the QuantiTect Primer Assay (Qiagen, Germany). The PCR was conducted using a 7900HT Sequence
Detection System (Applied Biosystems, Austin, TX, USA). All of the reactions were run in triplicate. The relative expression levels of the different miRNAs were calculated based on U6 RNA levels and multiplied by $10^2$. The relative expression levels of the mRNAs were calculated based on GAPDH levels and multiplied by $10^2$.

**Statistical analysis**
Each experiment was repeated at least three times. The continuous variables were expressed as the mean values ± standard deviations (SD). The Student’s $t$-test was used to analyze the different genes between cell lines with different drug sensitivities. A $P<$0.05 was considered statistically significant. All of the statistical analyses, including the normalization of data, choosing the differentially expressed genes and hierarchical clustering, were processed through GeneSpring GX Software.

**MiRNAs targets prediction**
The target genes of the miRNAs were predicted through miRGen, which incorporates algorithms including TargetScan, miRanda and PicTar (http://www.diana.pcbi.upenn.edu/cgi-bin/miRGen).

**Gene ontology and pathway analysis**
The gene ontology and pathway analysis was conducted through GenMAPP2 (http://www.genmapp.org/). The permuted $P$-value cutoff was set below 0.05, and the Z-score was set higher than 2.

**Results**

**The growth inhibition effects of HCPT on human gastric cancer cells**
Six human gastric cancer cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS) were used for the HCPT sensitivity analysis. The SRB assay showed a significant difference in sensitivities among these six cell lines at each concentration of HCPT. The concentration leading to 50% growth inhibition (GI50) was significantly different between the BGC-823 and AGS cell lines (Figure 1A). When exposed to HCPT at 1.0 µg/mL (the human peak plasma concentration), the AGS cells died, while the BGC-823, SGC-7901, MGC-803, HGC-27, and NCI-N87 cell lines displayed 24%, 36%, 65%, 72%, and 90% growth inhibition respectively, compared to the control (Figure 1B). In terms of percentage growth inhibition, there were significant differences ($P<$0.05) among the six cell lines, and they could be sorted according to their sensitivity to HCPT in ascending order: BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS.

**MiRNA expression profiling in HCPT-resistant versus HCPT-sensitive gastric cancer cell lines**
To investigate the role of miRNAs in intrinsic HCPT resistance, we conducted a comprehensive miRNA expression profiling of the six gastric cancer cell lines using the Agilent Human miRNA Microarray V2.0. This microarray contains 15744 probes representing 723 human miRNAs. After quantile normalization and filtering on flags (present or marginal), 279 miRNAs were selected for further analysis. ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPT-sensitive) cell lines with a more than 1.5-fold change ($P<$0.05) (Figure 2A). Further exploration of the other cell lines that had intermediate HCPT sensitivity (SGC-7901, MGC-823, HGC-27, and NCI-N87) revealed 25 miRNAs whose expression levels were also intermediate. Compared with their sensitive counterparts, 12 miRNAs were downregulated and the rest were upregulated in HCPT-resistant gastric cancer cells (Table 1). These results indicated that these 25 miRNAs might play important roles in intrinsic HCPT resistance. Hierarchical cluster analysis based on the expression patterns of these 25 miRNAs accurately separated the HCPT-sensitive cell line from the HCPT-resistant cell lines (Figure 2B).

To validate the miRNA microarray results, 12 deregulated miRNAs were randomly chosen for analysis by qRT-PCR. These miRNAs were miR-196a, miR-365, miR-424, miR-99b,
miR-98, miR-224, miR-338-3p, miR-141, miR-200a, miR-200b, miR-372, and miR-373. The qRT-PCR results confirmed the miRNA microarray results (Figure 3). MiR-196a, miR-365, miR-424, miR-99b, and miR-98 were expressed in both the HCPT-sensitive cell lines and the HCPT-resistant cell lines. Cells with higher expression levels of miR-196a, miR-365, miR-424, and miR-98 or lower levels of miR-99b were less sensitive to HCPT. MiR-224 and miR-338-3p were only expressed in HCPT-resistant cells, and miR-141, miR-200a, miR-200b, miR-372, and miR-373 were only expressed in HCPT-sensitive cells. These results indicated that the sensitivity to HCPT of human gastric cancer cell lines may be interfered by the intrinsic expression levels of miRNAs.

Identification of mRNA expression profiles in HCPT-resistant versus HCPT-sensitive gastric cancer cell lines

To explore the impact of gene expression on HCPT sensitivity, we further studied the mRNA expression patterns of these human gastric cancer cell lines using the Affymetrix HG-U133+PM Array Plate. In total, 307 genes were identified as differentially expressed between the HCPT-resistant cell lines and the HCPT-sensitive cell lines. The six cell lines clustered into different groups based on the expression profiles of the 307 genes (Figure 4A). Among these genes, 33 had been reported to be involved in cancer development, cell progression and/or chemoresponse (Figure 4B). Some of the genes are apoptosis-related genes (BAX, TIAL1, TPD52L1, BAG, SP3,
RPS27L, PLSCR3, TP53INP1, etc), cell division-related genes (MCM2, etc), cell adhesion/migration-related genes (TIMP2, VSNL1, FUT8, TBX3, etc) and checkpoint genes (RAD1, etc).

To validate the microarray data, nine differentially expressed genes were randomly chosen for qRT-PCR. The results showed that these genes were differentially expressed between different cell lines (Figure 5). Gene ontology and pathway enrichment analysis of these 307 genes demonstrated that two significant pathways \((P<0.05)\) were involved: the irinotecan pathway and the IL-3 pathway. The irinotecan pathway is very important for the biotransformation of CPTs, and the IL-3 pathway is related to the proliferation and differentiation of hematopoietic cells. In addition, we examined the focal adhesion pathway and the cell cycle pathway and achieved a \(P\)-value of 0.1.

### Integrated analysis of deregulated miRNAs and mRNAs

miRNAs modulate gene expression through inducing mRNA degradation or translational repression, or both. Therefore, we further performed an integrated analysis of miRNA and mRNA expression patterns in the six gastric cancer cell lines. The target genes of the 25 deregulated miRNAs were predicted using the intersections of PicTar and TargetScanS in mirGen (http://www.diana.pcbi.upenn.edu/cgi-bin/mirGen) to reduce the chance of false positives. For each deregulated miRNA, 13 to 600 target genes were predicted. As was expected, many known chemoresistant targets were found among the candidates, including CDKN1B (p27), ANXA1 (p35), PDCD4, UGT1A1, TOP1, CYP3A4, ABCG2 (BCRP), CHEK1, TDP1, BCL-2, and SUMO1. The pathways of these predicted target genes were enriched using GenMAPP 2. We also identified 47 biological pathways \((permutated \, P-value<0.05)\), including classical cancer-related pathways (EGFR1, Wnt signaling, MAPK signaling, C-kit receptor, focal adhesion pathways, etc); drug metabolism-associated pathways (cytochrome P450, etc) and cell apoptosis-related pathways (SIP signaling pathway, etc). Fifty percent of these 47 biological pathways had been reported to be implicated in carcinogenesis or chemoresponse (Figure 6A). Moreover, the gene ontology terms of these target genes included cell cycle, cell proliferation, G1/S transition of the mitotic cell cycle, negative regulation of programmed cell death, cell adhesion, positive regulation of cell motility, cell-matrix adhesion and regulation of DNA repair (Figure 6B). These results indicated that the cells were not sensitive to HCPT partially due to their resistance to HCPT.

### Table 1. miRNAs correlated to intrinsic HCPT resistance in gastric cancer cells.

| miRNA   | Regulation in resistant cells | Chromosome location |
|---------|-------------------------------|---------------------|
| miR-132 | Up                            | 17p13.3             |
| miR-224 | Up                            | Xq28                |
| miR-338-3p | Up                       | 17q25.3             |
| miR-452 | Up                            | Xq28                |
| miR-141 | Down                          | 12p13.31            |
| miR-200a | Down                       | 1p36.33             |
| miR-200b | Down                       | 1p36.33             |
| miR-200c | Down                       | 12p13.31            |
| miR-371-3p | Down                   | 19q13.41           |
| miR-371-5p | Down                   | 19q13.41           |
| miR-372  | Down                          | 19q13.41            |
| miR-373  | Down                          | 19q13.41            |
| miR-429  | Down                          | 1p36.33             |
| let-7g   | Up                            | 3p21.1              |
| miR-126  | Up                            | 9q34.3              |
| miR-196a | Up                            | 17q21.32.12q13.13   |
| miR-196b | Up                            | 7p15.2              |
| miR-19b  | Up                            | 13q31.3 Xq26.2      |
| miR-27a  | Up                            | 19p13.12            |
| miR-31   | Down                          | 9p21.3              |
| miR-365  | Up                            | 16p13.12 17q11.2    |
| miR-424  | Up                            | Xq26.3              |
| miR-7    | Down                          | 9q21.32 15q26.1 19p13.3 |
| miR-98   | Up                            | Xp11.22             |
| miR-99b  | Down                          | 19q13.33            |

### Table 2. The miRNA-mRNA regulation pairs.

| Regulation in resistant cells | miRNA   | Target genes                                           |
|-------------------------------|---------|--------------------------------------------------------|
| miRNA up-target down          | let-7g  | BTG2, VSNL1, MAP4K4, SLC35D2, CHD7, FRAS1, EPHA4, PGM2L1 |
| has-mir-19b                   | ADD3, EFNB2, STRN3, GAD1, SPHK2, VPS37B, TP53INP1, PGM2L1, BMP2R |
| has-mir-132                   | BTG2, SOX2 |
| has-mir-224                   | SOCS2, JAG1, AMIGO2 |
| has-mir-338                   | HIATL1 |
| has-mir-365                   | ADD3, KALRN |
| has-mir-424                   | ACTR1A, PSEN3, BTG2, EFN2, PDLIM5, PTPN3, SLC12A2, EPHA1, PIK3R1, ATF7IP2, SEH1L, AXIN2, WDR22, KALRN, PGM2L1 |
| has-mir-452                   | EIF2S1 |
| has-mir-98                    | BTG2, VSNL1, MAP4K4, SLC35D2, CHD7, FRAS1, EP HA4, PGM2L1 |
| miRNA down-target up          | has-mir-200a | OLFM1 |
| has-mir-200b                  | MITF, GABARAPL2, SLC38A2, FBXL16, NOG |
| has-mir-200c                  | MITF, GABARAPL2, SLC38A2, FBXL16, NOG |
| has-mir-141                   | OLFM1, GLRX, GABARAPL2, HOKA11, BCOR |
| has-mir-429                   | MITF, PCTK1, GABARAPL2, SLC38A2, FBXL16, NOG, SP3 |
| has-mir-7                     | SLC38A2 |
| has-mir-31                    | OSBP2 |
| has-mir-372                   | SMAD2, SAV3H1 |
| has-mir-373                   | SMAD2, SAV3H1 |
increased proliferation, anti-apoptosis and/or migration abilities.

Finally, we deciphered the relationship between the deregulated miRNAs and the mRNAs. Among the 307 differentially expressed mRNAs, 50 genes are the predicted targets of the 25 differential miRNAs, forming 78 relation pairs (Table 2). These 50 genes included tumor suppressors, protein kinases, helicases, histone methyltransferases, transcription factors and proteasome-related proteins. The tumor suppressor gene BTG2, which inhibits proliferation and promotes the apoptosis of gastric cancer cells, was targeted by the highly-expressed miRNAs let-7g, miR-98, and miR-132 in HCPT-resistant cells. Another tumor suppressor gene VSNL1, which inhibits cell migration, was also targeted by let-7g and miR-98. TP53INP1, which promotes TP53 phosphorylation on “Ser-46” and subsequent apoptosis, was predicted to be a target of miR-19b, an upregulated miRNA in HCPT-resistant cells. In addition, we found the components of cancer-related pathways such as SMAD2 and PIK3R1 in the relation pairs. Our systematic analysis revealed that approximately 1.3% of the predicted

---

**Figure 3.** Validation of the differentially expressed miRNAs by real-time PCR. As described in the Materials and Methods, real-time PCR was performed in triplicate, and the relative expression levels of different miRNAs were calculated based on U6 RNA levels and multiplied by $10^2$. MiR-196a, -365, -424, -98, -338, and -224 were markedly upregulated in the resistant cells, but not in the sensitive cells, while miR-99b, -141, -200a, -200b, -372, and -373 were markedly downregulated.
Figure 4. The mRNA expression signatures in HCPT-resistant versus HCPT-sensitive gastric cancer cells. The tree was based on the log2 transformation of the normalized probe signal intensity using hierarchical clustering. (A) The hierarchical clustering was based on 307 differentially expressed mRNAs whose expression levels were deregulated in HCPT-resistant cell lines. (B) The hierarchical clustering was based on 33 differentially expressed genes that were reported to be involved in cancer progression or chemoresponses.
miRNA targets formed the reciprocal “up-down” or “down-up” expression relationships with miRNAs. On the one hand, miRNAs modulate gene expression through both mRNA degradation and translational repression mechanisms, and on the other hand, miRNA-mRNA regulatory networks are highly complex.

Discussion

Cancer drug resistance can be classified into acquired and intrinsic resistance. Acquired drug resistance is induced during the process of drug treatment, while intrinsic resistance is the inherent characterization of the original cells before drug treatment. For studying acquired resistance, drug-induced resistant cell lines are used as a model, and the acquired resistance mechanism is determined by comparing the characterization before and after drug treatment. However, for studying intrinsic resistance, untreated original cells are usually used for drug sensitivity assays, and these results indicate the original cell’s drug response and give indications for clinical drug treatment. Previous studies of cancer drug resistance have mainly focused on DNA, mRNA and protein levels\(^\text{[16]}\). Different cells appear to achieve the same end result by modulating a definitive number of genes through different mechanisms\(^\text{[17]}\). Among these mechanisms, miRNA is a newly identified mechanism, and this field is potentially promising. The NCI-60s, a panel of 60 diverse human cancer cell lines established by the National Cancer Institute, have been profiled for their miRNA expression\(^\text{[18]}\). Using the expression data of the NCI-60 and their corresponding drug sensitivities, miRNA profiles were developed to represent the sensitivities to individual chemotherapeutic agents\(^\text{[19]}\). However, gastric cancer cell lines were not included in the NCI-60. Therefore, in this study, we examined the role of miRNAs in the intrinsic drug resistance of gastric cancer cell lines. Our results will benefit both the understanding of drug resistance mechanisms and the prediction of clinical drug responses.

First, to explore this new field, we examined the miRNA expression profiles of six gastric cancer cell lines. We identified 25 deregulated miRNAs, and the results were confirmed by qRT-PCR. The miRNA expression pattern was efficient to separate the six cell lines in terms of HCPT sensitivity. Interestingly, some of the deregulated miRNAs were from the same family, and they may produce synergistic effects in mediating the resistant phenotype. Among the 12 downregulated miR-
NAs, the miR-200 family was only expressed in the HCPT-sensitive cell line AGS. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration through the direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2[20]. In addition, the overexpression of miR-141 in the gastric cancer cell lines was correlated with the inhibition of cell proliferation [21]. MiR-7 inhibits the epidermal growth factor receptor and the Akt pathway in cancer cell lines (lung, breast, and glioblastoma), inducing cell cycle arrest and cell death[22, 23]. MiR-31 inhibits breast cancer metastasis and was shown to be downregulated in gastric cancer tissues [24]. We predicted that the downregulation of these miRNAs could promote cancer cell migration and cell proliferation, thus impairing the HCPT-induced responses. Among the 13 upregulated miRNAs, miR-338 and miR-126 were identified as the signature miRNAs for predicting the survival of gastric cancer patients [25]. MiR-98 and let-7g may play roles in both the apoptotic and cell-proliferation pathways [26], and tumor-suppressor gene FUS1 is a target of miR-98[27]. MiR-196a promotes the oncogenic phenotype of colorectal cancer cells by activating the AKT signaling pathway and promoting cancer cell detachment, migration and invasion[28]. MiR-27a functions as an oncogene in gastric adenocarcinoma by targeting an anti-proliferative protein prohibitin[29], and downregulation of miR-27a could reverse the multidrug resistance of esophageal cancer[30]. The upregulation of these miRNAs may strengthen cell proliferation or reduce apoptosis and therefore render cells insensitive to HCPT. Although no related reports have indicated the involvement of the other deregulated miRNAs in carcinogenesis and chemoresponses, we believe a detailed

Figure 6. Gene ontology and pathway enrichment of predicted miRNA targets. (A) Significant pathways were enriched by GenMAPP2. The listed pathways are related to cell apoptosis or proliferation and have a P-value less than 0.05. The black column represents the number of target genes located in the pathway, while the white column represents the number of total genes located in the pathway. (B) Gene ontology was also enriched by GenMAPP2. The results indicated that these differential miRNAs may regulate genes involved in cell adhesion, cell proliferation and programmed cell death. The Z-score represents the enrichment extent, and the number listed beside each gene ontology term is the P-value.
study on these miRNAs is warranted.

Gene ontology and pathway enrichment analysis based on the 307 differentially expressed miRNAs revealed only two significant pathways with \( P \)-values < 0.05, including the irinotecan pathway and the IL-3 pathway. In the irinotecan pathway, we found that ABCG2 was downregulated in the HCPT-resistant cell lines; this result was in agreement with a previous report that the ABCG2 protein mediated drug efflux from resistant cells and was directly involved in cellular resistance to SN38 (the active metabolite of irinotecan)\(^{[31]}\). We also found that UGT1A10 and UGT1A6, which catalyze the glucuronidation of SN-38, were only expressed in HCPT-sensitive cell lines; this result disagreed with the putative view that SN-38 glucuronidation could lead to cellular resistance to irinotecans. Therefore, these results indicated that the sensitivity of cells to HCPT was affected by multiple factors that contribute simultaneously.

To study the involvement of miRNA-mediated regulation of gene expression in HCPT resistance, we analyzed whether the 307 genes were the predicted targets of the 25 deregulated miRNAs, and finally, we found 50 genes and 78 relation pairs between them. However, we could not examine the enriched pathways of these 50 genes to analyze them individually. Some of these genes are tumor suppressor genes involved in regulating cancer cell proliferation or apoptosis. Because miRNAs are predicted to target multiple unrelated genes that are not coexpressed and one target gene is predicted to be targeted by multiple miRNAs, it is not surprising that miRNA expression levels do not tend to be strongly correlated with particular target transcripts. This phenomenon was also presented in Blower’s study on the NCI-60\(^{[18]}\).

This study was based on six gastric cancer cell lines, and we gained some information for intrinsic drug resistance, but more cell lines and clinical samples will need to be analyzed in a future study.

Conclusions
Our study demonstrated that the intracellular levels of miRNAs may interfere the chemoresponses of gastric cancer cells partially due to the regulation of cancer cell proliferation, migration and cell death pathways. Hierarchical clustering based on the expression patterns of 25 miRNAs showed that cell groupings were generally consistent with HCPT sensitivity. The mRNA signature we observed was also informative for discriminating cell lines with different sensitivities to HCPT. In addition, we found a slightly lower correlation between the expression patterns of miRNAs and those of their predicted target transcripts. Our study provides a resource for integrated chemo-genomic studies aimed to elucidate the molecular markers for personalized therapy and to understand the mechanisms of HCPT resistance.

Acknowledgements
This research was supported by grants from the National High-Tech Program “863” (2006AA020704).

Author contribution
Xue-mei Wu designed the study, performed the SRB assay, microarray experiments and real-time PCR experiments, analyzed the data and wrote the manuscript. Li ZHU, Xian-xin MENG, and Xiao-na ZHANG performed the microarray experiments and generated the microarray data. Xiang-qiang SHAO, Shi-xu LIU, and Jian LIN performed the miRNA prediction and analysis. Hua-sheng XIAO coordinated the study and reviewed the manuscript. All of the authors have read and approved the final manuscript.

References
1 Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354–62.
2 Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351–75.
3 Lippert TH, Ruoff HJ, Volm M. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung 2008; 58: 261–4.
4 Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008; 65: 3145–67.
5 Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615–27.
6 Mimeault M, Hauke R, Batra SK. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 2008; 83: 673–91.
7 Beretta GL, Perego P, Zunino F. Mechanisms of cellular resistance to camptothecins. Curr Med Chem 2006; 13: 3291–305.
8 Saleem A, Edwards TK, Rasheed Z, Rubin EH. Mechanisms of resistance to camptothecins. Ann N Y Acad Sci 2000; 922: 46–55.
9 Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 2003; 22: 7296–304.
10 Lee YS, Dutta A. MicroRNAs: small but potent oncogenes or tumor suppressors. Curr Opin Investig Drugs 2006; 7: 560–4.
11 Caledas C, Brenton JD. Sizing up miRNAs as cancer genes. Nat Med 2005; 11: 712–4.
12 Sassen S, Miska EA, Caledas C. MicroRNA: implications for cancer. Virchows Arch 2008; 452: 1–10.
13 Calif GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004; 101: 2999–3004.
14 Bertino JR, Banerjee D, Mishra PJ. Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. Pharmacogenomics 2007;8: 1625–7.
15 Wu XM, Xiao HS. miRNAs modulate the drug response of tumor cells. Sci China C Life Sci 2009; 52: 797–801.
16 Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008; 7: 1–9.
17 Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 2007; 10: 59–67.
18 Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 2007; 6: 1483–91.
19 Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, et al. An integrated approach to the prediction of
chemotherapeutic response in patients with breast cancer. PLoS ONE 2008; 3: e1908.

20 Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910–4.

21 Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T, et al. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol 2009; 44: 556–61.

22 Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008; 68: 3566–72.

23 Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009; 284: 5731–41.

24 Zhang Y, Guo J, Li D, Xiao B, Miao Y, Jiang Z, et al. Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Med Oncol 2010; 27: 685–9.

25 Li X, Zhang Y, Zhang Y, Ding J, Wu K, Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010; 59: 579–85.

26 Wang Y, Lee CG. MicroRNA and cancer—focus on apoptosis. J Cell Mol Med 2009; 13: 12–23.

27 Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 2009; 7: 1234–43.

28 Schimanski CC, Frierichs K, Rahman F, Berger M, Lang H, Galle PR, et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol 2009; 15: 2089–96.

29 Liu T, Tang H, Lang Y, Liu M, Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 2009; 273: 233–42.

30 Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010; 55: 2545–51.

31 Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F, et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer 2004; 109: 848–54.